🇺🇸 Palbociclib PD-0332991 in United States

47 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Asthenia — 6 reports (12.77%)
  2. Confusional State — 5 reports (10.64%)
  3. Nausea — 5 reports (10.64%)
  4. Neutrophil Count Decreased — 5 reports (10.64%)
  5. Pleural Effusion — 5 reports (10.64%)
  6. Pneumonia — 5 reports (10.64%)
  7. Acute Kidney Injury — 4 reports (8.51%)
  8. Dyspnoea — 4 reports (8.51%)
  9. Failure To Thrive — 4 reports (8.51%)
  10. Fall — 4 reports (8.51%)

Source database →

Other Oncology approved in United States

Frequently asked questions

Is Palbociclib PD-0332991 approved in United States?

Palbociclib PD-0332991 does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Palbociclib PD-0332991 in United States?

GBG Forschungs GmbH is the originator. The local marketing authorisation holder may differ — check the official source linked above.